AbbVie Raises Guidance Based On Humira Patent Umbrella
This article was originally published in Scrip
Analyst buzz about the AbbVie Inc. third quarter earnings call Oct. 30 centered on its strongly optimistic sales guidance through 2020, based on its belief in a suite of intellectual property that it says will protect top-seller Humira from US biosimilar competition until 2022 or later.
You may also be interested in...
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Weeks after lifting of an FDA clinical hold, CymaBay says it will resume development of its PPAR agonist in primary biliary cholangitis. It will initiate a new Phase III trial but also use data from a terminated Phase III study.